News

Behavioral Therapy Halves Persistent Postprostatectomy Incontinence

View on the News

Is This as Good as It Gets?

The study findings appear encouraging at first glance, but it is important to examine them more closely before advocating this behavioral intervention in routine practice, said Dr. David F. Penson.

First, although episodes of urinary leakage declined from 28 to "only" 13 episodes per week with the active treatment, this still means that patients had an average of 2 such episodes per day instead of 3. This level of continuing incontinence certainly would be problematic for many men.

Second, although approximately 60% of the men who underwent active treatment used fewer urinary protection pads or diapers after 8 weeks, that still leaves approximately 40% who used the same number as they did at baseline. Would these patients conclude that behavioral treatment was successful?

Behavioral therapy "likely requires considerable patient and clinician time and effort," which many may not consider to be worth the limited benefits reported here.

Dr. Penson is in urologic surgery at Vanderbilt University and the VA Tennessee Valley Geriatric Research, Education, and Clinical Center, Nashville. He reported no financial conflicts of interest. These comments are taken from his editorial accompanying Dr. Goode’s report (JAMA 2011;305:197-8).


 

FROM JAMA

The study findings clearly show that behavioral therapy should be offered to all men with persistent postprostatectomy urinary incontinence "because it can yield significant durable improvement in incontinence and quality of life, even years after radical prostatectomy," Dr. Goode and her associates noted.

They added that two good resources for locating qualified behavioral therapy in such patients are the National Association for Continence and the Wound, Ostomy, and Continence Nurses Society.

This study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases and the Department of Veterans Affairs Birmingham-Atlanta Geriatric Research, Education, and Clinical Center. Dr. Goode reported receiving a research grant from Pfizer. Her associates reported ties to Astellas, GlaxoSmithKline, Vantia, Boehringer-Ingelheim, Ferring, Johnson & Johnson, Allergan, Indevus, and Novartis.

Pages

Recommended Reading

FDA Panel Reviews BPH Drugs for Reducing Prostate Cancer Risk
MDedge Internal Medicine
Acetylcysteine Nixed for Prevention of Contrast-Induced Nephropathy
MDedge Internal Medicine
Outcomes of Acute Kidney Injury in Cancer Patients Studied
MDedge Internal Medicine
Severe Incontinence More Likely to Respond to Transurethral Bulking Agent
MDedge Internal Medicine
Race, Poverty Affect Transplant Outcomes in Children
MDedge Internal Medicine
Video Report: Challenges for Urogynecologic Research
MDedge Internal Medicine
Weekend Admission Predicts Higher Mortality in ESRD Patients
MDedge Internal Medicine
Markers May Guide Need for Dialysis After Cardiac Surgery
MDedge Internal Medicine
Extremely-Low-Birth-Weight Infants Need Prolonged Renal Follow-Up
MDedge Internal Medicine
Higher Mortality When Anemia Develops in Stage 3 Kidney Disease
MDedge Internal Medicine